Printer Friendly

LIDAK PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE

 LIDAK PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE
 LA JOLLA, Calif., Nov. 6 /PRNewswire/ -- Lidak Pharmaceuticals


(NASDAQ: LDAKU,LDAKA) announced today that its board of directors has relieved Fred A. Espinosa of his duties as the company's president and chief operating officer. There are no plans to replace Espinosa at this time and his duties will be divided among senior management.
 Lidak Pharmaceuticals develops and commercializes innovative pharmaceutical and other significant products for the health care field. The company has entered into a 20-year technology license agreement with Medical Biology Institute ("MBI"), a nonprofit research organization, which gives Lidak exclusive marketing rights to products and technology developed by the institute. Through its license with MBI, Lidak is developing new therapeutic approaches for cancer, AIDS and autoimmune diseases. In addition, the company is developing its proprietary compound, Lidakol(TM), as a treatment for oral and genital herpes infections and other applications.
 -0- 11/6/91
 /CONTACT: David H. Katz, M.D., chairman and CEO, 619-450-1538, or Michael H. Lorber, vice president and CFO, 619-558-0364, both of Lidak Pharmaceuticals; or Elizabeth Gard or Roger Pondel of Rifkind Pondel & Parsons, 310-207-9300, for Lidak Pharmaceuticals/
 (LDAKU,LDAKA) CO: Lidak Pharmaceuticals, Medical Biology Institute ST: California IN: MTC SU: PER SE-EH -- LA012 -- 1538 11/06/91 08:32 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 6, 1991
Words:211
Previous Article:INTEGRATED HEALTH SERVICES ANNOUNCES MEDICAL SPECIALTY UNIT DEVELOPMENT PLAN FOR 1992; COMPANY TO INCREASE MSUs BY 60 PERCENT FOR 1992
Next Article:FIRST CONSTITUTION GRANTS COMMON STOCK TO BANK EMPLOYEES
Topics:


Related Articles
LIDAK PHARMACEUTICALS ANNOUNCES RESIGNATIONS
LIDAK PHARMACEUTICALS ISSUES STATEMENT ON RESIGNATION OF DONALD E. MOSLER
LIDAK PHARMACEUTICALS ELECTS NEW DIRECTOR
LIDAK PHARMACEUTICALS APPOINTS VICE PRESIDENT OF BUSINESS DEVELOPMENT AND LICENSING
LIDAK PHARMACEUTICALS APPOINTS NEW BOARD MEMBER
LIDAK PHARMACEUTICALS REAPPOINTS OFFICERS, APPROVES NEW CONTRACT WITH CEO AND APPOINTS CHAIRMAN
LIDAK PHARMACEUTICALS APPOINTS NEW VICE PRESIDENT AND CHIEF FINANCIAL OFFICER
LIDAK ANNOUNCES RETURN OF FORMER CHIEF FINANCIAL OFFICER
LIDAK PHARMACEUTICALS APPOINTS GERALD J. YAKATAN AS VICE PRESIDENT, DRUG DEVELOPMENT
LIDAK Pharmaceuticals Appoints Susan Yeagley Sullivan As New Chief Financial Officer

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters